Cargando…

Large Prostate Volume Does Not Negatively Impact Health-Related Quality of Life in Patients with Prostate Cancer Treated with Ultrahypofractionated Stereotactic Body Radiotherapy

Background: Survival outcomes after primary radiotherapy for localized prostate cancer (PCa) are excellent, regardless of the specific treatment modality. For this reason, health-related quality of life (HRQOL) has come to play an ever more important role in treatment selection. Stereotactic body ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milecki, Piotr, Adamska, Anna, Rucinska, Anna, Pałucki, Grzegorz, Szumiło, Agnieszka, Skrobała, Agnieszka, Jodda, Agata, Michalak, Michał
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967077/ https://www.ncbi.nlm.nih.gov/pubmed/36836467 http://dx.doi.org/10.3390/jpm13020233

Ejemplares similares

Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost
por: Skrobala, Agnieszka, et al.
Publicado: (2023)

Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
por: Ishiyama, Hiromichi, et al.
Publicado: (2021)

Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer
por: Yoshioka, Yasuo, et al.
Publicado: (2023)

Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer
por: Mohajer, Jonathan, et al.
Publicado: (2020)

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer: Toxicity and quality of life assessment
por: Rucinska, Monika, et al.
Publicado: (2016)

Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer
por: Wolf, Frank, et al.
Publicado: (2020)

Dosimetric Comparison of Ultra-Hypofractionated and Conventionally Fractionated Radiation Therapy Boosts for Patients with High-Risk Prostate Cancer
por: Piotrowski, Tomasz, et al.
Publicado: (2022)

Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022)

Factors influencing quality of life in patients during radiotherapy for head and neck cancer
por: Żmijewska-Tomczak, Małgorzata, et al.
Publicado: (2013)

Prostate Ultrahypofractionation – Rising to Challenges Presents Opportunities in the COVID-19 Era
por: Griffiths, W., et al.
Publicado: (2021)

MRI-Guided Radiation Therapy for Prostate Cancer: The Next Frontier in Ultrahypofractionation
por: Benitez, Cecil M., et al.
Publicado: (2023)

Criteria for Verification and Replanning Based on the Adaptive Radiotherapy Protocol “Best for Adaptive Radiotherapy” in Head and Neck Cancer
por: Bak, Bartosz, et al.
Publicado: (2022)

Early toxicities of ultrahypofractionated stereotactic body radiotherapy for intermediate risk localized prostate cancer using cone-beam computed tomography and real-time three-dimensional transperineal ultrasound monitoring
por: Lee, Eric Ka-Chai, et al.
Publicado: (2021)

Ultra-Hypofractionated Proton Therapy in Localized Prostate Cancer: Passive Scattering versus Intensity-Modulated Proton Therapy
por: Borowicz, Dorota Maria, et al.
Publicado: (2021)

Stereotactic Ablative Radiotherapy for Prostate Cancer—The Treatment Results of 500 Patients and Analysis of Failures
por: Miszczyk, Leszek, et al.
Publicado: (2019)

Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?
por: Milecki, Tomasz, et al.
Publicado: (2015)

A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial
por: Pasquier, David, et al.
Publicado: (2023)

Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art
por: Milecki, Piotr, et al.
Publicado: (2010)

Dosimetric evaluation of photons versus protons in postmastectomy planning for ultrahypofractionated breast radiotherapy
por: Oonsiri, Puntiwa, et al.
Publicado: (2022)

Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer
por: Levin-Epstein, Rebecca, et al.
Publicado: (2020)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Case report: Ultrahypofractionated palliative breast radiotherapy for a fungating invasive mammary carcinoma
por: Hong, Yejun, et al.
Publicado: (2023)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

One-Year Toxicity of Ultrahypofractionated Breast Radiotherapy (+/- Sequential Boost) and a Survey of Patient Experience
por: Nicholson, J., et al.
Publicado: (2022)

Does CyberKnife Improve Dose Distribution Versus IMRT and VMAT on a Linear Accelerator in Low-risk Prostate Cancer?
por: Borowicz, Dorota Maria, et al.
Publicado: (2022)

Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer
por: Milecki, Piotr, et al.
Publicado: (2009)

Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer
por: Corrigan, Kelsey L., et al.
Publicado: (2021)

Stereotactic body radiotherapy for organ-confined prostate cancer
por: Katz, Alan J, et al.
Publicado: (2010)

Stereotactic ablative body radiotherapy in patients with prostate cancer
por: Loblaw, Andrew, et al.
Publicado: (2018)

Stereotactic radiotherapy of the prostate: fractionation and utilization in the United States
por: P. Weiner, Joseph, et al.
Publicado: (2017)

Cellular Damage in the Target and Out-Of-Field Peripheral Organs during VMAT SBRT Prostate Radiotherapy: An In Vitro Phantom-Based Study
por: Piotrowski, Igor, et al.
Publicado: (2022)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Stereotactic radiotherapy for prostate cancer: A review and future directions
por: Syed, Yusef A, et al.
Publicado: (2017)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Plan comparison of prostate stereotactic radiotherapy in spacer implant patients
por: Oki, Yuya, et al.
Publicado: (2021)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Tomotherapy – a different way of dose delivery in radiotherapy
por: Piotrowski, Tomasz, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ne5558g384m44vr0nu248l8tdd